Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin or Melatonin with FDC in Locally Advanced Breast Cancer
NCT02506777Phase 2Unknown
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
- Start
- Jul 2015
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin and melatonin in breast cancer (3 arms), sponsored by N.N. Petrov National Medical Research Center of Oncology. Primary endpoints: Response rate at 6 months and Pathomorphological response at 6 months. Status: unknown.
02
Drugs
metforminmelatonin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02506777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02506777.